NurExone Biologic Inc.
NRX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -6.31M | -6.47M | -6.38M | -6.54M | -6.32M |
| Total Depreciation and Amortization | 215.00K | 198.00K | 185.00K | 171.00K | 142.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.63M | 1.45M | 1.32M | 1.29M | 1.28M |
| Change in Net Operating Assets | -190.00K | 68.00K | 372.00K | 4.00K | 297.00K |
| Cash from Operations | -4.65M | -4.76M | -4.51M | -5.07M | -4.61M |
| Capital Expenditure | -21.00K | -25.00K | -55.00K | -92.00K | -381.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 1.00K | 1.00K |
| Cash from Investing | -21.00K | -25.00K | -55.00K | -91.00K | -380.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -35.00K | -27.00K | -22.00K | -19.00K | -19.00K |
| Issuance of Common Stock | 4.42M | 5.58M | 5.86M | 5.03M | 3.96M |
| Repurchase of Common Stock | -- | -- | -- | -- | -44.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 33.00K | -- | -- | -1.28M | 35.00K |
| Cash from Financing | 4.41M | 5.55M | 5.83M | 3.74M | 3.94M |
| Foreign Exchange rate Adjustments | 51.00K | 159.00K | 170.00K | -116.00K | -107.00K |
| Miscellaneous Cash Flow Adjustments | -16.00K | -- | -- | -- | -- |
| Net Change in Cash | -222.00K | 922.00K | 1.44M | -1.54M | -1.16M |